Brief: Bridgebio Reports Positive Phase 3 Topline Results For Oral Infigratinib
12/02/2026 13:03
Feb 12 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO REPORTS POSITIVE PHASE 3 TOPLINE RESULTS FOR ORAL INFIGRATINIB WITH THE FIRST STATISTICALLY SIGNIFICANT IMPROVEMENTS IN BODY PROPORTIONALITY IN ACHONDROPLASIA Source text: ID:nGNXcBnQH Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels